Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3 extension study of dazukibart in adults with dermatomyositis or polymyositis
MOH_2025-12-11_015531Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of dazukibart in Autoimmune Myopathies, dermatomyositis (DM) and polymyositis (PM) (4 cohorts), sponsored by Pfizer. Primary endpoint: Long-term safety of dazukibart. Started Dec 2025; status: recruiting.
02
Drugs
dazukibart
03
Conditions
Autoimmune Myopathiesdermatomyositis (DM)polymyositis (PM)
Beyond the preview
Go deeper on MOH_2025-12-11_015531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-12-11_015531.